Attack Life Sloan Foundation

10/05/2026

10/02/2026

💙

09/30/2026

A Major Victory for the ALS Community!

The U.S. Senate has passed the House’s version of the ACT for ALS Reauthorization Act, sending the legislation to the President’s desk for final signature.

This bipartisan achievement will extend the landmark 2021 ACT for ALS, helping ensure continued access to promising experimental treatments, advance critical research, support innovative clinical trials, and strengthen the infrastructure needed to accelerate therapies for ALS and other rare neurodegenerative diseases.

This demonstrates that bipartisan support for the ALS community remains strong. Together, we are sustaining momentum, advancing therapeutic development, and creating greater opportunities for people living with ALS.

We celebrate this important step forward!💙

09/27/2026

NEWS: Ulefnersen has met its primary endpoint in the Phase 3 FUSION trial, showing a statistically significant benefit in function and survival for people living with FUS-ALS compared with placebo.

Read the full article in the link in our bio.

06/30/2026

05/24/2026

https://www.facebook.com/share/p/18o1HLY9FF/?mibextid=wwXIfr

ALS treatment research is continuing to evolve as an experimental oral therapy recently received FDA fast track designation: https://bit.ly/4dF9RpH

Read more about how researchers are approaching nerve cell communication in ALS, and why this update is gaining attention in ongoing ALS clinical trials and experimental treatment development. Researchers are continuing to explore new pathways that could shape future ALS treatment options, adding to broader conversations around research, symptom progression, and emerging therapies.

05/04/2026

https://www.facebook.com/share/p/18CA46DfX9/?mibextid=wwXIfr

BREAKING NEWS: On the first day of the Senate version of the ACT for ALS Reauthorization Act (S.4472) has officially been introduced.

This bipartisan legislation would help build on the progress being made to accelerate ALS research, expand access to investigational therapies, and strengthen the infrastructure helping move promising research and treatments forward.

Reauthorizing ACT for ALS means continuing to invest in what is working and ensuring we do not miss this moment when we are on the cusp of real breakthroughs.

Tell Congress to support the ACT for ALS Reauthorization Act: alsnetwork.quorum.us/campaign/152857/

02/05/2026

Appropriations bill H.R. 7148 has passed, increasing federal funding for ALS research by $45M for a total of $313M – the most we’ve ever had!

This happened because of your advocacy and continued efforts. Community is powerful!

🙏Thank your senators and representatives today who voted "yes" for passing this bill.

01/10/2026

For the first time, amyotrophic lateral sclerosis has a treatment shown to slow underlying nerve damage. A landmark clinical trial found that Tofersen reduced biomarkers of motor neuron injury and slowed muscle decline in patients with ALS caused by the SOD1 gene mutation.

ALS has long had no therapies that directly alter disease biology. Tofersen works by targeting the genetic source of toxic SOD1 protein buildup, reducing stress on motor neurons rather than only addressing symptoms after damage occurs.

While the treatment applies only to a subset of ALS patients with this specific mutation, researchers describe it as a historic step forward. It represents the first credible evidence that ALS progression can be slowed, opening the door to future therapies for broader forms of motor neuron disease.

Source/Credit: The New England Journal of Medicine — Tofersen ALS clinical trial
Shared for informational/Educational purpose only